Postconditioning: a Form of "modified Reperfusion" Protects the Myocardium by Activating the Phosphatidylinositol 3-kinase-Akt Pathway
Overview
Affiliations
Brief intermittent episodes of ischemia and reperfusion, at the onset of reperfusion after a prolonged period of ischemia, confer cardioprotection, a phenomenon termed "ischemic postconditioning" (Postcond). We hypothesized that this phenomenon may just represent a modified form of reperfusion that activates the reperfusion injury salvage kinase (RISK) pathway. Isolated perfused rat hearts were subjected to: (a) 35 minutes of ischemia and 120 minutes of reperfusion, and infarct size was determined by tetrazolium staining; or (b) 35 minutes of ischemia and 7 minutes of reperfusion, and the phosphorylation states of Akt, endothelial NO synthase (eNOS), and p70S6K were determined. Postcond reduced infarct size from 51.2+/-3.4% to 31.5+/-4.1% (P<0.01), an effect comparable with ischemic preconditioning (IPC; 27.5+/-2.3%; P<0.01). Of interest, the combined protective effects of IPC and Postcond were not additive (30.1+/-4.8% with IPC+Postcond; P=NS). Inhibiting phosphatidylinositol 3-kinase (PI3K) at reperfusion using LY or Wortmannin (Wort) during the first 15 minutes of reperfusion completely abolished Postcond-induced protection (31.5+/-4.1% with Postcond versus 51.7+/-4.5% with Postcond+LY, P<0.01; 56.2+/-10.1% with Postcond+ Wort; P<0.01), suggesting that Postcond protects the heart by activating PI3K-Akt. Western blot analysis demonstrated that Postcond induced a significant increase in phosphorylation of Akt, eNOS, and p70S6K in an LY- and Wort-sensitive manner. In conclusion, we show for the first time that ischemic Postcond protects the myocardium by activating the prosurvival kinases PI3K-Akt, eNOS, and p70S6K in accordance with the RISK pathway.
Al-Othman R, Al-Jarallah A, Babiker F Front Pharmacol. 2024; 15:1398630.
PMID: 39611167 PMC: 11603114. DOI: 10.3389/fphar.2024.1398630.
Doul J, Minarikova M, Charvatova Z, Maxova H Physiol Rep. 2024; 12(15):e16147.
PMID: 39097984 PMC: 11298247. DOI: 10.14814/phy2.16147.
Bergman I, Gelikas S, Wexler Y, Braver O, Boyle D, Nussinovitch U Open Heart. 2024; 11(1).
PMID: 38286569 PMC: 10826564. DOI: 10.1136/openhrt-2023-002281.
Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets.
Zhang M, Liu Q, Meng H, Duan H, Liu X, Wu J Signal Transduct Target Ther. 2024; 9(1):12.
PMID: 38185705 PMC: 10772178. DOI: 10.1038/s41392-023-01688-x.
The RISK pathway leading to mitochondria and cardioprotection: how everything started.
Yellon D, Beikoghli Kalkhoran S, Davidson S Basic Res Cardiol. 2023; 118(1):22.
PMID: 37233787 PMC: 10220132. DOI: 10.1007/s00395-023-00992-5.